• Microbubble contrast agents bearing conjugation chemistries suitable for binding various targeting ligands.
• Microbubble contrast agents coated with specific targeting ligands for molecular imaging.
• For imaging and quantifying blood flow and microvascular perfusion.
Targestar™-P is an ultrasound contrast agent useful for vascular imaging and quantitation of blood flow. Targestar-P is intended for use in small animal models of disease. Agents may be administered as an intravenous bolus injection for routine contrast ultrasound imaging, or as a continuous venous infusion for sensitive perfusion measurements. Bolus administration can be accomplished via retro-orbital, tail vein, or jugular injection in mice.
Details: 2 x 0.3 ml Vial. Each vial contains approximately 10 mouse doses.
B. TargestarTM-B (TS-107)
Targestar-B is an ultrasound contrast agent that is coated with biotin. The agent can be subsequently derivatized with streptavidin, using the provided conjugation kit. Biotinylated ligands, such as peptides, antibodies, and glycoconjugates, can then be bound to the surface of the agents by biotin-streptavidin conjugation chemistry.
Details: 2 x 1.5 ml Vials Targestar-B, Conjugation Reagent, Targestar Buffer. Each vial contains approximately 10 mouse doses. Also can be used for in vitro studies of targeted microbubbles.
C. TargestarTM-SA (TS-201)
Targestar-SA is an ultrasound contrast agent that is coated with streptavidin. Biotinylated ligands, such as peptides, antibodies, and glycoconjugates, can be bound to the surface of the agents using biotin-streptavidin conjugation chemistry.
Details: 2 x 1 ml Vials Targestar-SA, Targestar Buffer. Microbubble contrast agent coated with streptavidin for easy 1-step conjugation of biotinylated ligands. Each vial results in approximately 10 mouse doses.
D. VisistarTM-Integrin (TS-101)
Visistar-Integrin is a microbubble ultrasound contrast agent containing a cyclic RGD targeting ligand. Visistar-Integrin is known to bind to alpha-v beta-3 integrin found on angiogenic vascular endothelium. The agent is useful for imaging angiogenesis in small animal models of tumor development. Agents are administered as an intravenous bolus injection, via retro-orbital, tail vein, or jugular injection in mice.
Details: 1 x 0.3 ml Vial. Each vial contains approximately 10 mouse doses.
Targeson is a biotechnology company that develops, manufactures, and markets ultrasound contrast agent technologies for pre-clinical molecular imaging in animal models. Targeson is also developing this technology for site-specific diagnosis and therapy in humans. The company has engineered a versatile microparticle platform that may be used as both a contrast agent and, in a slightly modified form, a drug or gene delivery agent. Targeson manufactures and sells the TargestarTM line of contrast agents for ultrasound-based molecular and functional imaging in animal models of disease. Targeson’s agents can be readily targeted to the unique molecular signature of many diseases, and can be used to detect pathophysiology on the molecular level. The company’s innovative intellectual property enables the agents to bind with high efficiency to the intended molecular targets. In addition, the company is investigating therapeutic technology for simultaneous imaging and delivery, which enables the user to verify that the therapeutic compound has been delivered to the intended site. Targeson is headquartered in San Diego, CA.
